ONCY
HEALTHCAREOncolytics Biotech Inc
$0.92+0.01 (+0.55%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ONCY Today?
No stock-specific AI insight has been generated for ONCY yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.33$1.51
$0.92
Fundamentals
Market Cap$105M
P/E Ratio—
EPS$-0.30
Dividend Yield—
Dividend / Share—
ROE-7.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding116.1M
ONCY News
20 articles- Oncolytics Biotech Reports Data in Colorectal Cancer StudyYahoo Finance·May 6, 2026
- Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal CancerYahoo Finance·May 4, 2026
- CEO Chat with Jared Kelly, CEO of Oncolytics BiotechYahoo Finance·May 1, 2026
- ONCY: Initiating Coverage of Oncolytics Biotech; A Focused Path to Unlocking the Potential of PelareorepYahoo Finance·Apr 7, 2026
- Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal CancerYahoo Finance·Apr 6, 2026
- Oncolytics Biotech’s Nevada Move Resets Capital Access And Dilution Trade OffYahoo Finance·Apr 1, 2026
- Oncolytics Biotech® Completes Domicile Change to the United StatesYahoo Finance·Apr 1, 2026
- Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026Yahoo Finance·Mar 19, 2026
- Oncolytics Biotech® Launches Randomized Colorectal Cancer StudyYahoo Finance·Mar 2, 2026
- Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal CancerYahoo Finance·Feb 24, 2026
- Assessing Oncolytics Biotech (ONCY) Valuation After FDA Fast Track Designation For PelareorepYahoo Finance·Feb 16, 2026
- Why Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant Colorectal CancerYahoo Finance·Feb 15, 2026
- Oncolytics receives FDA Fast Track Designation for pelareorepYahoo Finance·Feb 5, 2026
- Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightYahoo Finance·Feb 4, 2026
- Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal CancerYahoo Finance·Feb 4, 2026
- Oncolytics Biotech® Announces Results of Special Meeting of ShareholdersYahoo Finance·Jan 15, 2026
- Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead BiostatisticsYahoo Finance·Jan 14, 2026
- Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal CancerYahoo Finance·Jan 12, 2026
- Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep AdvancesYahoo Finance·Jan 12, 2026
- Oncolytics outlines strategic rationale for proposal to change jurisdictionYahoo Finance·Jan 10, 2026
All 20 articles loaded
Price Data
Open$0.90
Previous Close$0.92
Day High$0.92
Day Low$0.87
52 Week High$1.51
52 Week Low$0.33
52-Week Range
$0.33$1.51
$0.92
Fundamentals
Market Cap$105M
P/E Ratio—
EPS$-0.30
Dividend Yield—
Dividend / Share—
ROE-7.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding116.1M
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a developing-stage biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of cancer. The company is headquartered in Calgary, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—